NCT04855123

Brief Summary

Chronic kidney failure in the single remaining kidney is one of the dreaded complications of nephrectomy in patients operated on for cancer-related reasons (1). Indeed, chronic kidney disease (CKD) is associated with major cardiovascular morbidity and mortality (2). To date, there are few non-invasive methods available to predict the onset and progression of CKD in patients for whom nephrectomy is indicated. Preoperative creatinine and glomerular filtration rate are poor predictors of the subsequent risk of single kidney failure (1). Early predictive markers could help anticipate the management of CKD in patients for whom progression to end-stage renal disease is predictable. Furthermore, such markers could be used as a decision-making aid to specify the type of nephrectomy to be preferred (total versus partial nephrectomy). The state of microcirculation, particularly retinal, is correlated with the progression of certain conditions such as diabetic nephropathy (3-5). A new technique for evaluating retinal microcirculation called OCT-A (an imaging technique in ophthalmology allowing a precise non-invasive study of the retinal microvascular network) has recently been used by our team to highlight an association between retinal vascularisation and the level of cardiovascular risk in a population of coronary patients without diabetes (6). We hypothesize that the observation of retinal vascular abnormalities could reflect changes in kidney structure that could underlie chronic renal failure. The aim of this work is thus to evaluate whether the presence of abnormalities in the retinal microvascularisation is 1) predictive of the deterioration in renal function one year after nephrectomy for cancer-related reasons and 2) correlated with renal histological abnormalities.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Mar 2021

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 18, 2021

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

April 19, 2021

Completed
3 days until next milestone

First Posted

Study publicly available on registry

April 22, 2021

Completed
4.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 5, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 5, 2026

Completed
Last Updated

April 27, 2026

Status Verified

April 1, 2026

Enrollment Period

5 years

First QC Date

April 19, 2021

Last Update Submit

April 22, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Decline in renal function one year after nephrectomy

    defined in a given patient as the occurrence of a Glomerular Filtration Flow Rate (CKD/EPI equation) of less than 60ml/min/1.73 m2

    One year after nephrectomy

Study Arms (1)

patient

OTHER
Other: retinal imagingOther: paraclinical surveillance

Interventions

OCT-angiography, Retinophotography, ocular fundus, Pulsed air tonometer

patient

blood and urine sampling, assessment of kidney function with creatinine, protein, albumin levels and CKD-EPI equation)

patient

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult patient
  • Indication for total nephrectomy for kidney cancer decided with a multidisciplinary oncology consultation
  • Kidney scan images available
  • Patient affiliated to French national health insurance
  • Patient who has given oral consent

You may not qualify if:

  • Pregnant woman
  • Ophthalmologic history (macular vascular or degenerative diseases, epiretinal membranes, glaucoma)
  • Cannot sit still for 60 minutes
  • Metastatic cancer
  • Single functional kidney before nephrectomy
  • Estimated Glomerular Filtration Flow Rate (CKD-EPI formula) less than 60 mL/min/1.73m2
  • Diabetes type 1 or type 2
  • HIV, HCV or HBV positive serology
  • Patient subject to a measure of legal protection (guardianship, curatorship, etc.)
  • Patient with increased pressure during the measurement of the intraocular pressure before dilation
  • Patient with histological abnormalities suggestive of nephropathy (excluding nephroangiosclerosis) or ischemic parenchymal sequelae of renal vein thrombosis in the pathological analysis of the nephrectomy sample

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Chu Dijon Bourgogne

Dijon, 21000, France

Location

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 19, 2021

First Posted

April 22, 2021

Study Start

March 18, 2021

Primary Completion

March 5, 2026

Study Completion

March 5, 2026

Last Updated

April 27, 2026

Record last verified: 2026-04

Locations